BRAF and neoplasm: Our analysis showed that MPAS varied across tumor tissue types independently of RAS or BRAF mutational status, supporting the idea of a potential disconnection between mutation status and the activity of the MAPK pathway (Fig. 2a) and highlighting the inadequacy of using solely RAS/RAF mutational status as predictive biomarkers in clinical trials of MEK1/2 inhibitors.